SCYNEXIS Announces $40.0 Million Private Placement

Rhea-AI Summary

SCYNEXIS (NASDAQ: SCYX) entered a private placement expected to close on or about April 1, 2026, generating approximately $40.0 million upfront and up to $52.2 million more if Common Warrants are fully exercised, subject to stockholder approval.

The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants and accompanying Common Warrants for an aggregate of 43,500,000 warrants; combined prices were $0.92 and $0.9199. The financing extends cash runway into mid-2029 and includes institutional investors and CEO participation.

Positive

• Upfront proceeds of approximately $40.0 million
• Potential additional $52.2 million if Common Warrants are fully exercised
• Issuance completed to institutional investors including Great Point Partners and Adage
• CEO participation by Dr. David Angulo
• Estimated cash runway extended into mid-2029
• Registration rights agreed for resale of issued shares

Negative

• Issuance of 34,750,000 common shares creates significant dilution potential
• Up to 43,500,000 Common Warrants outstanding could further dilute upon exercise
• Warrants exercisable only after stockholder approval, creating execution risk
• Low combined sale price of $0.92 per unit may pressure existing share value

Key Figures

Upfront gross proceeds: $40.0 million Additional warrant proceeds: $52.2 million Common shares issued: 34,750,000 shares +5 more

8 metrics

Upfront gross proceeds $40.0 million Anticipated gross proceeds from private placement before fees

Additional warrant proceeds $52.2 million Potential gross proceeds if Common Warrants fully exercised for cash

Common shares issued 34,750,000 shares Common stock to be issued in private placement

Pre-funded warrants 8,750,000 warrants Pre-Funded Warrants to purchase common stock

Common warrants 43,500,000 warrants Common Warrants to purchase common stock or pre-funded warrants

CEO participation 108,695 shares Common Shares and accompanying Common Warrants sold to CEO

Offering price (shares) $0.92 Combined price per Common Share and accompanying Common Warrant

Warrant exercise price $1.20 Exercise price per share for Common Warrants

Market Reality Check

Price: $0.7897 Vol: Volume 81,424 is about 72...

low vol

$0.7897 Last Close

Volume Volume 81,424 is about 72% below the 20-day average of 288,012, suggesting limited pre-news activity. low

Technical Shares at $0.7897 are trading modestly above the 200-day MA of $0.76 and about 39.7% below the 52-week high.

Peers on Argus

Sector peers show mixed moves with no clear trend: IXHL down 5.3%, TLPH down 2.0...

1 Down

Sector peers show mixed moves with no clear trend: IXHL down 5.3%, TLPH down 2.03%, AYTU up 1.35%, others flat to slightly lower. Momentum scanner flags only GELS down ~4.84%, reinforcing a stock-specific context for this private placement.

Historical Context

5 past events · Latest: Mar 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Full-year earnings	Positive	+2.3%	2025 results with GSK payment and >2-year cash runway update.
Feb 26	Clinical trial start	Positive	-0.7%	First participants dosed in Phase 1 IV SCY-247 SAD/MAD trial.
Jan 28	Scientific presentations	Positive	-3.2%	IMARI data highlighting potent antifungal activity of SCY-247.
Jan 21	FDA designations	Positive	+4.0%	FDA QIDP and Fast Track status granted for SCY-247 program.
Dec 22	Nasdaq compliance	Negative	-2.3%	180-day extension to regain minimum bid price compliance.

Pattern Detected

Recent news often skews positive, but price reactions are mixed, with several positive catalysts followed by selling pressure and regulatory/earnings updates seeing more aligned moves.

Recent Company History

Over the past six months, SCYNEXIS reported multiple milestones around its antifungal pipeline and GSK partnership. Earnings on Mar 4, 2026 highlighted stronger 2025 revenue and an extended cash runway. Clinical and scientific updates for SCY‑247 in early 2026 drew mixed to negative price reactions, while FDA QIDP/Fast Track designations on Jan 21, 2026 and Nasdaq’s bid-price extension in Dec 2025 aligned with modest gains or declines. Today’s private placement adds a significant equity financing layer to that trajectory.

Market Pulse Summary

This announcement details a sizeable private placement providing anticipated upfront gross proceeds ...

Analysis

This announcement details a sizeable private placement providing anticipated upfront gross proceeds of $40.0 million, plus potential additional proceeds from 43.5 million Common Warrants. The financing significantly increases the share count but, according to the company, supports operations into mid‑2029, including development of SCY‑770 for ADPKD. Investors may track execution on clinical milestones, timing of stockholder approval for additional authorized shares, and the pace of any warrant exercises.

Key Terms

private placement, securities purchase agreement, pre-funded warrants, common warrants, +3 more

7 terms

private placement financial

"announced that it has entered into a securities purchase agreement..."

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

securities purchase agreement financial

"announced that it has entered into a securities purchase agreement..."

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

pre-funded warrants financial

"pre-funded warrants to purchase up to 8,750,000 shares of common stock..."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

common warrants financial

"accompanying common warrants to purchase up to an aggregate 43,500,000 shares..."

A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.

accredited investors financial

"with certain new and existing institutional and accredited investors."

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

registration statement regulatory

"agreed to file a registration statement with the Securities and Exchange Commission..."

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

registration rights agreement regulatory

"the Company and the investors entered into a registration rights agreement..."

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

AI-generated analysis. Not financial advice.

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors. The Company anticipates upfront gross proceeds from the private placement to be approximately $40.0 million, before deducting placement agent fees and transaction-related expenses, and up to an additional $52.2 million in gross proceeds if the Common Warrants are fully exercised for cash, subject to Stockholder Approval of shares of common stock issuable upon exercise of the Common Warrants. The private placement is expected to close on or about April 1, 2026, subject to the satisfaction of customary closing conditions.

Pursuant to the terms of the securities purchase agreement, the Company will issue an aggregate of (i) 34,750,000 shares of its common stock, $0.001 par value per share (the “Common Shares”), (ii) pre-funded warrants to purchase up to 8,750,000 shares of common stock (the “Pre-Funded Warrants”) and (iii) accompanying common warrants to purchase up to an aggregate 43,500,000 shares of common stock or pre-funded warrants in lieu thereof (the “Common Warrants”). The aggregate share issuance includes 108,695 Common Shares and accompanying Common Warrants that were sold to the Company’s President and Chief Executive Officer, Dr. David Angulo. Each Common Share (or Pre-Funded Warrant) will be accompanied by one Common Warrant. The Common Shares and accompanying Common Warrants were sold at a combined price of $0.92 per Common Share and accompanying Common Warrant, and 8,750,000 Pre-Funded Warrants and accompanying Common Warrants were sold at a combined price of $0.9199 per Pre-Funded Warrant and accompanying Common Warrant.

Each Pre-Funded Warrant is immediately exercisable and will expire when exercised in full. Each Common Warrant will be exercisable for one share of common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.20 per share, will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase in the Company’s authorized shares of common stock (the “Stockholder Approval”) and will expire on 5:00 p.m. (New York City time) on the earlier of (i) the fifth anniversary of the closing date and (ii) the 30th day after the Company publicly releases topline data at Week 48 from its Phase 2 proof-of-concept clinical study evaluating SCY-770 in patients with ADPKD.

The private placement financing includes participation from new and existing institutional investors, including Great Point Partners, LLC, Squadron Capital Management LLC, Adage Capital Management, L.P., Propel Bio Partners, a large healthcare-dedicated fund, and other investors. The Company’s President and Chief Executive Officer, Dr. David Angulo, is also participating in the private placement.

Guggenheim Securities, LLC is acting as the sole placement agent for the private placement.

The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes. Based on the Company’s current plans, the Company estimates its existing cash, cash equivalents and marketable securities, together with the anticipated net proceeds from the private placement (excluding potential proceeds from the exercise of any Common Warrants), will be sufficient to fund its operations into mid-2029.

The offer and sale of the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with entering into the securities purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the Common Shares issued in the private placement, including the shares of common stock underlying the Pre-Funded Warrants and accompanying Common Warrants sold in this financing. In connection with the private placement, the Company has agreed to convene a stockholder meeting no later than 90 days following the closing to seek approval of an increase in the number of its authorized shares of common stock.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: statements concerning expected gross proceeds from the private placement, expected use of proceeds, and expected closing of the private placement, the ability to obtain Stockholder Approval for the exercise of the Common Warrants into shares of common stock, and other statements identified by words such as “will,” “potential,” “could,” "can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products and risks related to the private placement. For the Company, this includes satisfaction of the customary closing conditions of the private placement, delays in obtaining required stock exchange or other regulatory approvals, the potential exercise of the warrants and gross proceeds generated by any warrant exercises, the future prospects of the Company’s SCY-770 program, the timing and results of the Company’s anticipated Phase 2 proof-of-concept clinical study evaluating SCY-770, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and the impact of instability in general business and economic conditions, including changes in inflation and interest rates. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation, its most recent Annual Report on Form 10-K filed on March 4, 2026, including under the caption "Risk Factors,” and in other filings the Company makes with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations
Irina Koffler LifeSci Advisors Tel: 917-734-7387
ikoffler@lifesciadvisors.com

Source: Scynexis

FAQ

How much cash will SCYNEXIS (SCYX) raise in the March 31, 2026 private placement?

SCYNEXIS expects approximately $40.0 million in upfront gross proceeds, with potential additional proceeds. According to the company, up to $52.2 million more may be raised if Common Warrants are fully exercised, subject to stockholder approval.

What securities did SCYNEXIS (SCYX) issue in the April 1, 2026 private placement?

The company will issue common shares, pre-funded warrants, and common warrants. According to the company, that includes 34,750,000 common shares, 8,750,000 pre-funded warrants, and up to 43,500,000 Common Warrants.

What are the exercise terms of the Common Warrants issued by SCYNEXIS (SCYX)?

Each Common Warrant is exercisable at $1.20 per share and expires on defined timelines. According to the company, exercise begins after stockholder approval and ends at the earlier of five years or 30 days after Week 48 topline data release.

How will SCYNEXIS (SCYX) use proceeds from the private placement announced March 31, 2026?

Proceeds are intended for working capital and general corporate purposes. According to the company, anticipated net proceeds plus existing cash and securities are expected to fund operations into mid-2029.

Who participated in SCYNEXIS's (SCYX) March 31, 2026 private placement and who acted as placement agent?

New and existing institutional investors participated, and Guggenheim Securities acted as placement agent. According to the company, participants include Great Point Partners, Squadron Capital, Adage Capital, Propel Bio Partners, and the CEO.